Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) lead candidate tecarfarin, a next-generation Vitamin K antagonist (VKA), recently received FDA Orphan Drug Designation to prevent blood clots and strokes in patients with implanted mechanical circulatory support devices such as a left ventricular assist device (LVAD). Cadrenal intends to pursue a pivotal trial evaluating tecarfarin’s effectiveness for LVAD patients and demonstrate its advantages over warfarin, the sole lifelong blood thinner option used off-label for these patients. Our Chief Medical Officer, Douglas Losordo, MD, is passionate about Cadrenal's commitment to develop and market a new therapeutic to improve clinical outcomes for LVAD patients.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) lead candidate tecarfarin, a next-generation Vitamin K antagonist (VKA), recently received FDA Orphan Drug Designation to prevent blood clots and strokes in patients with implanted mechanical circulatory support devices such as a left ventricular assist device (LVAD). Cadrenal intends to pursue a pivotal trial evaluating tecarfarin’s effectiveness for LVAD patients and demonstrate its advantages over warfarin, the sole lifelong blood thinner option used off-label for these patients. Our Chief Medical Officer, Douglas Losordo, MD, is passionate about Cadrenal's commitment to develop and market a new therapeutic to improve clinical outcomes for LVAD patients.

Jeff Cole, Chief Commercial Officer of Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), attended the BIO International Conference last week in San Diego alongside more than 20,000 industry professionals and investors from around the world. Jeff is responsible for business development and met with various companies to discuss partnership opportunities. Jeff shared: "This year's BIO was especially active with in-depth discussions about groundbreaking therapies and medical device advancements. I participated in the dealmaking track that focused on meeting potential clinical and commercial partners and investors."

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is thrilled to share news of an important clinical trial analysis reinforcing our belief in the need for our next-generation Vitamin K Antagonist (VKA) tecarfarin to improve anticoagulation and outcomes for LVAD patients.    Abbott Inc. sponsored the trial and analysis and presented the results at the ISHLT - International Society for Heart and Lung Transplantation 44th Annual Conference. We commend Abbott for its commitment to LVAD patients.    Cadrenal intends to pursue a pivotal trial evaluating tecarfarin effectiveness for LVAD patients. Read more: https://lnkd.in/dzWvHReU   #cadrenal #nasdaq #cvkd #therapeutics #tecarfarin Quang Pham Matthew Szot

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024   Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.   Company WebcastThe webcasted presentation will take place at 12:30pm ET on Thursday, May 30, 2024. webcast will also be available for replay following the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lnkd.in/ebvv-ZUE.   https://lnkd.in/gemGsU4a                                                                                                                                                                                                                                                                              #cadrenal #nasdaq #cvkd #therapeutics #tecarfarin Quang Pham Matthew Szot  

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) Provides First Quarter 2024 Corporate Update   Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.   https://lnkd.in/g7-ctMbD #Cadrenal #Nasdaq #CVKD #Biotech #Innovation #Tecarfarin Quang Pham Matthew Szot

Join us for a recap of the recent presentation at Noble Capital's conference, where Cadrenal Therapeutics, Inc. (CVKD) was spotlighted. Our CEO, Quang Pham, along with Robert Leboyer, Senior Biotechnology Analyst at Noble Capital, and Doug Losordo, Chief Scientific Officer, shared insights into our innovative therapies for neurological disorders. With over 11 clinical trials and proven efficacy, Tecarfarin, our lead candidate, a novel oral anti-coagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, offers a stable anti-coagulation solution where existing options fall short. Stay tuned for trial initiations and regulatory updates as Cadrenal Therapeutics, Inc. (CVKD) advances towards FDA submission. #Cadrenal #Nasdaq #CVKD #Biotech #Innovation #Tecarfarin Cadrenal Therapeutics, Inc. - NOBLE Capital Markets Virtual Healthcare Conference Replay (youtube.com) - https://lnkd.in/d5mA_aHt

Cadrenal Therapeutics, Inc. Therapeutics is thrilled to announce our participation in the NOBLE Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024! Join us to learn about tecarfarin, our innovative anticoagulant, in a fireside style Q&A session. Save the Date: April 18, 2024 at 1:00pm ET. For registered investors, don't miss the opportunity to schedule 1x1 meetings with our management team.   Learn more at www.cadrenal.com or contact Matthew Szot, CFO, at press@cadrenal.com.   https://lnkd.in/giHGWdWK   #CadrenalTherapeutics #HealthcareInnovation #VirtualConference #CVKD

We are thrilled to announce that Cadrenal Therapeutics, Inc. has received FDA Orphan Drug Designation (ODD) for tecarfarin, our novel blood thinner, aimed at preventing thromboembolism and thrombosis in patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts.    This designation not only provides potential market exclusivity for up to seven years after approval, but also opens up expanded partnering opportunities for tecarfarin.    At Cadrenal, we are deeply committed to addressing unmet needs in anticoagulation therapy. With this second FDA ODD, we're one step closer to making a meaningful difference in the lives of patients with rare cardiovascular conditions who require chronic anticoagulation.    Read more about this milestone: https://lnkd.in/gkdCV25y   #CadrenalTherapeutics #FDAODD #OrphanDrugDesignation #novelbloodthinner #Tecarfarin #HealthcareInnovation #CVKD Quang Pham

When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer   Anticoagulation therapy (AT) is fundamental in atrial fibrillation (AF) treatment but poses challenges in implementation, especially in AF populations with elevated thromboembolic and bleeding risks. Current guidelines emphasize the need to estimate and balance thrombosis and bleeding risks for all potential candidates of antithrombotic therapy. However, administering oral AT raises concerns in specific populations, such as those with chronic kidney disease (CKD), coagulation disorders, and cancer due to lack of robust data. These groups, excluded from large direct oral anticoagulants trials, rely on observational studies, prompting physicians to adopt individualized management strategies based on case-specific evaluations. �� https://lnkd.in/gVrDRkti   Cadrenal Therapeutics, Inc. is focused on developing tecarfarin, aimed at patients with rare cardiovascular conditions requiring chronic anticoagulation therapy. Existing treatments, such as warfarin and direct-acting oral anticoagulants (DOACs) like Eliquis and Xarelto, often do not meet the needs of these patients. Tecarfarin is being developed as a safer and more effective treatment option, specifically for individuals with implanted medical devices such as left ventricular assist devices (LVADs), end-stage kidney disease (ESKD) and atrial fibrillation (AF) and thrombotic antiphospholipid syndrome (APS). This initiative is a critical step towards providing enhanced therapeutic options for cardiovascular care. #cadrenal #nasdaq #cvkd #therapeutics #tecarfarin